title: Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia.
abstract: Kinetic parameters including potential doubling time (Tpot), duration of S phase (Ts), labelling index (LI), and DNA index (DI) were obtained from 42 dogs with previously untreated lymphoma. Standard flow cytometric techniques using BrdUrd were employed. All dogs were treated with L-asparaginase and remission was induced in 26 dogs, which were then randomized to receive chemotherapy only (doxorubicin [DOX] alone or with lonidamine) or chemotherapy plus whole body hyperthermia (WBH). Dogs were treated every 3 weeks for up to five treatments and evaluated every 3 weeks for evidence of tumour recurrence. Within this subset of animals there was no difference in outcome based on treatment group. Median values for Tpot, Ts and LI were 3.4 days, 7.23 h and 12.49%, respectively. Dogs that had tumours with LI > or = 20% had a shorter time until recurrence than dogs with tumours characterized by LI < 20%. In dogs treated only with chemotherapy, dogs bearing tumours with longer than median Tpot and Ts values and lower than median LI had significantly longer remission duration than dogs with more rapidly proliferating tumours. Dogs treated only with chemotherapy, which had longer than median Tpot and Ts values and lower than median LI, had significantly longer remission duration than all other dogs in the study. The mechanisms in which kinetics are associated with response to chemotherapy are not clear and vary depending on tumour type and treatment regimen. More work is needed to understand factors involved in cell killing during in vivo hyperthermia.
authors.affiliation: Department of Radiological Health Sciences, Colorado State University, College of Veterinary Medicine and Biomedical Sciences, Fort Collins 80523, USA. slarue@vth.colostate.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Larue
authors.forename: M H
authors.initials: MH
authors.lastname: Fox
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: R L
authors.initials: RL
authors.lastname: Page
authors.forename: D M
authors.initials: DM
authors.lastname: Getzy
authors.forename: D E
authors.initials: DE
authors.lastname: Thrall
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: M W
authors.initials: MW
authors.lastname: Dewhirst
authors.forename: E L
authors.initials: EL
authors.lastname: Gillette
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002453:Cell Cycle; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000188:drug therapy / Q000628:therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D006979:Hyperthermia, Induced; D007191:Indazoles / Q000008:administration & dosage; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy* / Q000662:veterinary; D011379:Prognosis
chemical_list: D007191:Indazoles; D004317:Doxorubicin; C016371:lonidamine